analyst day review leverag
disrupt biopharma servic
believ iqvia hit mark compani analyst day tuesday
effect commun uniqu posit help address custom
challeng given foundat asset analyst day mark iqvia second
updat investor sinc octob merger quintil im
opinion thesi transit iqvia disrupt much
iqvia disrupt present clear us compani made
lot progress leverag technolog data invest drive new solut
biopharma custom across clinic trial technolog solut given
iqvia integr strategi scale custom reach believ compani
well posit execut attract end market fund drive acceler
top bottom line growth
look iqvia forecast medium-term revenu growth
came expect m-hsd growth pleas see
iqvia analyst day preview focu proof point strategi mid-
term guid guidanc mirror recent commentari growth inflect driven
outsiz new busi win well ramp new product
technolog busi includ oce oct iqvia forecast modest margin
expans drive ebitda growth compound-annual-growth-rate margin expans
cultur ceo bousbib compani laid new oper
excel program off-set continu invest
busi support compani growth strategi capit deploy iqvia
plan continu invest tuck-in share repurchas said iqvia
moder leverag target rang previous
expect compani maintain current leverag target although think
lower leverag help broaden compani investor base
potenti support multipl expans put togeth iqvia
forecast double-digit ep growth consist expect
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight believ iqvia creat
best class platform cro industri believ
marri quintil cro platform im clinic
insight yield market share gain time
earn growth
believ iqvia valu proposit could yield
market share gain time coupl long
runway cost synergi upsid case
repres upsid cash ep
risk around deploy relat major new
award could pressur margin expans csm
segment growth could weigh near-term result
downsid case repres
downsid cash ep
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
believ iqvia hit mark compani analyst day tuesday
effect commun uniqu posit help address custom
challeng given foundat asset analyst day mark iqvia second updat
investor sinc octob merger quintil im opinion
thesi transit iqvia disrupt much iqvia disrupt
present clear us compani made lot progress
leverag technolog data invest drive new solut biopharma
custom across clinic trial technolog solut given iqvia integr
strategi scale custom reach believ compani well posit
execut attract end market fund drive acceler top bottom line
growth
ep y/i growth
ceo bousbib strategi updat iqvia
ceo bousbib kick present overview iqvia success
track record prior multi-year target build confid
compani continu acceler top-lin growth next three year
reflect compani prior multi-year target iqvia track deliv
commit prior medium term guidanc call msd revenu
growth ebitda growth rate revenu growth ep growth
double-digit guidanc assum capit deploy accord leverag ratio
impli capit deploy buy-back tuck-in billion
annual expect deliv double-digit ep growth rel impli
target forecast current ahead revenu cash ep
barclay consensu estim rel impli guidanc
ceo bousbib discuss compani invest cost save target
last year notabl bousbib reiter iqvia track achiev
merger synergi target run-rat exit largest area cost save come
procur addit cost save bucket compani also
reinvest back busi time period includ
tuck-in softwar develop well invest compani
technolog infrastructur data scienc team
note base barclay estim
pleas see
focu proof point
look iqvia forecast medium-term revenu growth
came expect m-hsd growth guidanc mirror recent
manag commentari growth inflect driven outsiz new busi win
 well ramp new product technolog busi includ oce
oct ceo bousbib ad growth expect ramp three-year period
compani recent growth driver scale time segment perspect iqvia
forecast growth ta segment growth
segment well growth csm segment iqvia forecast modest
margin expans drive ebitda growth compound-annual-growth-rate margin expans
cultur ceo bousbib compani laid new oper
excel program compani largest opportun leverag lean
process although iqvia also see opportun drive save across procur
oper use artifici intelligence/machin learn off-set
continu invest busi support compani growth strategi
capit deploy iqvia plan continu invest tuck-in share
repurchas said iqvia moder leverag target rang
previous expect compani maintain current leverag target
think lower leverag help broaden compani investor
base potenti support multipl expans put togeth iqvia
reiter expect double-digit ep growth consist
cfo mike mcdonnel ad addit commentari compani medium-
term target ta segment iqvia target growth compound-annual-growth-rate includ
organ growth contribut organ growth would mark
acceler histor trend rang believ reflect
increment contribut iqvia execut opportun leverag technolog
asset across oce oct solut iqvia forecast ex-fx growth
view realist given compani recent new busi win momentum well
growth driver cro platform mcdonnel ad growth
underli basi similar headlin growth expect tailwind
off-set headwind pass-through revenu final csm busi
expect transit growth compani reorgan go-to-
market strategi forecast growth next three year term
cash flow iqvia expect invest approxim revenu capital-expenditure
assum free cash flow gener around convers net incom
compani expect invest annual toward tuck-in share repurchas
exit leverag
iqvia provid overview compani human data scienc cloud
underpin compani technolog real world clinic develop solut
combin world largest healthcar databas advanc analyt compani
aim effici creat relev fit-for-purpos data set iqvia goal streamlin
gather standard healthcar data time spent value-add
analys allow compani provid tailor insight specif given countri
therapeut area iqvia describ compani data metamorphosi engin
backbon human data scienc cloud differenti enabl data integr
alchemi transform data integr capabl allow compani
aggreg link signific amount healthcar data safe secur manner
data alchemi capabl iqvia use machin learn provid extend
enhanc fit-for-purpos applic lastli iqvia leverag data transform
ensur data meet standard clinic indic diseas model differ
countri iqvia describ compani ai capabl layer top cloud
improv valu data analyt cloud capabl
describ potenti replic iqvia believ level requir
invest necessari healthcar expertis import competit barrier
link togeth data set provid recommend client specif
circumst context healthcar expertis import differenti
compani believ competitor would replic four core cloud capabl
scale abl compet level
technolog solut molecul market
tal rosenburg svp global technolog solut led overview iqvia variou
technolog solut describ focu break silo within organ
way drive collabor increas effici custom iqvia leverag
expertis data technolog well market knowledg creat seri
connect platform help influenc right decis make mr rosenburg
size address technolog solut market includ
opportun clinic solut real-world evid complianc
commerci solut within technolog solut busi iqvia
made major invest iqvia human data scienc cloud focus work
best class platform catalyst salesforc partnership
orchestr clinic technolog oct platform oct platform iqvia intend
enhanc workflow clinic trial custom import valu add
consid around half clinic trial still run in-hous versu get
outsourc cro importantli ai util autom formerli manual function
addit platform seamlessli connect differ member clinic trial
team essenc oct close gap data captur decis make
lead quicker effici trial
rymsza vice-president global pharmacovigil regulatori technolog solut
describ iqvia complianc offer mr rymsza note complianc life
scienc industri becom increasingli difficult due abund silod data
system well constant chang regul iqvia global complianc platform
help compani rang complianc function includ plan execut
manag solut mr rymsza present scenario shelf life product
chang month system describ regulatori impact
chang propos regulatori action even built structur content
hugh phd svp world discuss import iqvia world
evid capabl link mani larg data set draw action insight
stress compani focu uphold privaci standard furthermor
discuss use rwe capabl across healthcar system includ
biopharma compani payor regul
aj ploszay vice-president global technolog solut describ uniqu element iqvia
newli introduc oce platform specif discuss import data flow
differ busi unit platform enabl better commun
launch month ago iqvia oce platform custom
user compani believ much upsid expect continu ad
custom platform jame hall director global technolog solut present
demo platform pharmaceut sale repres easili abl
identifi new sale lead base data member commerci
evid rwe capabl increasingli help client solv problem
healthcar landscap mr resnick size iqvia rwe busi roughli
growth expect doubl digit importantli iqvia believ
rwe busi play address market publish
evid trial expect includ rwe iqvia rwe platform current
util million de-identifi patient record million patient enrol real
world studi furthermor iqvia rwe platform current oper
countri use top biopharma compani one reason
iqvia success rwe adapt platform compar
provid tailor solut specif focus
world genom increasingli import sequenc cost declin becom
preval overal mr kotchi describ real world genom futur real world
evid size opportun grow doubl digit iqvia
partner import player genom genom england
sequenc genom
dr ashley woolmor svp head european data evid network
discuss use iqv real world evid platform healthcar regul
fda cdc nh iqvia also partner collabor oncolog data
eu code compris lead pharma compani iqvia rwe platform
import support collabor compani
smarter clinic develop power iqvia
richard staub head iqvia solut segment provid overview
presenc within cro industri iqvia largest global cro
contract backlog on-going studi oper countri
current address outsourc opportun mr staub believ
market growth driven innov oncolog therapeut area leverag
novel drug deliveri mechan given dynam iqvia note emerg
biopharma compani import sourc growth repres
drug develop pipelin molecul basi larg pharma remain
import custom class iqvia adapt oper model meet emerg
biopharma client need iqvia biotech platform approach entail come
custom flat organ offer differenti data solut tailor
special indic often target client
iqvia spent signific amount time discuss data analyt
capabl lead improv trial execut client outsiz busi
win enhanc execut address trial design trial start-up trial conduct trial
close benefit breadth depth compani data describ
human data scienc cloud section abil gather transform data
power compani data metamorphosi engin iqvia view
import differenti sinc merger octob compani attribut
award compani core-pow solut award split
total custom includ larg pharma emerg
biopharma client autom invest iqvia core-en offer
cover countri repres clinic trial site patient global
addit compani expand therapeut area address
platform cite ti capabl cover full servic pipelin
iqvia leverag machin learn artifici intellig ai improv
insight gain healthcar databas compani work
capabl three year ai-ded employe work
three dozen project util ai improv revenu new busi
award also improv effici run clinic trial could driver
margin time ai use optim protocol site select patient
recruit iqvia provid exampl innov applic sever health
condit find patient earli import look sever phenotyp trait iqvia
use ai predict patient certain diseas includ
clinic research program time fashion addit compani use ai
silico clinic research either predict efficaci advers event compani also
build silico capabl optim drug discoveri process
iqvia orchestr clinic technolog oct suit expect driver saas-
base revenu compani also stress relev typic program
 solut segment applic within platform help autom manual
task make user experi overal favor analyt screen
problem clinic data improv qualiti safeti clinic research
oct suit use common languag cut across interfac sponsor iqvia
patient investig facilit flow inform clinic research
associ cra clinic trial manag system ultim
electron trial master file etmf iqvia also leverag clinic technolog
enabl virtual clinic trial limit burden patient particip clinic
trial leverag technolog includ mobil health telemedicin capabl
compani studi hub platform clinic trial streamlin
patient investig
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
